Restasis Patent Redo Bid 'Inappropriate,' Fed. Circ. Told
The row over Allergan Inc.'s controversial deal to sell patents on the dry-eye drug Restasis to a Mohawk tribe to avoid the Patent Trial and Appeal Board continues, as generic makers...To view the full article, register now.
Already a subscriber? Click here to view full article